Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 193.18
EXAS's Cash to Debt is ranked higher than
69% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. EXAS: 193.18 )
Ranked among companies with meaningful Cash to Debt only.
EXAS' s 10-Year Cash to Debt Range
Min: 12.24  Med: 10000.00 Max: No Debt
Current: 193.18
Equity to Asset 0.93
EXAS's Equity to Asset is ranked higher than
97% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. EXAS: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
EXAS' s 10-Year Equity to Asset Range
Min: -0.41  Med: 0.69 Max: 0.96
Current: 0.93
-0.41
0.96
F-Score: 4
Z-Score: 59.02
M-Score: -99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2086.19
EXAS's Operating margin (%) is ranked lower than
93% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. EXAS: -2086.19 )
Ranked among companies with meaningful Operating margin (%) only.
EXAS' s 10-Year Operating margin (%) Range
Min: -51374.51  Med: -565.04 Max: 1150.29
Current: -2086.19
-51374.51
1150.29
Net-margin (%) -2075.25
EXAS's Net-margin (%) is ranked lower than
93% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.26 vs. EXAS: -2075.25 )
Ranked among companies with meaningful Net-margin (%) only.
EXAS' s 10-Year Net-margin (%) Range
Min: -46049.02  Med: -548.14 Max: 1123.53
Current: -2075.25
-46049.02
1123.53
ROE (%) -53.13
EXAS's ROE (%) is ranked lower than
77% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.76 vs. EXAS: -53.13 )
Ranked among companies with meaningful ROE (%) only.
EXAS' s 10-Year ROE (%) Range
Min: -505.37  Med: -63.34 Max: -26.92
Current: -53.13
-505.37
-26.92
ROA (%) -49.28
EXAS's ROA (%) is ranked lower than
77% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.65 vs. EXAS: -49.28 )
Ranked among companies with meaningful ROA (%) only.
EXAS' s 10-Year ROA (%) Range
Min: -95.07  Med: -50.56 Max: -18.9
Current: -49.28
-95.07
-18.9
ROC (Joel Greenblatt) (%) -648.84
EXAS's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. EXAS: -648.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3463.3  Med: -1546.40 Max: -637.37
Current: -648.84
-3463.3
-637.37
Revenue Growth (3Y)(%) -37.00
EXAS's Revenue Growth (3Y)(%) is ranked lower than
87% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. EXAS: -37.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXAS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -22.55 Max: 47.4
Current: -37
0
47.4
EBITDA Growth (3Y)(%) 30.50
EXAS's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. EXAS: 30.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EXAS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -39.4  Med: -14.35 Max: 45.4
Current: 30.5
-39.4
45.4
EPS Growth (3Y)(%) 31.50
EXAS's EPS Growth (3Y)(%) is ranked higher than
89% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. EXAS: 31.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EXAS' s 10-Year EPS Growth (3Y)(%) Range
Min: -43.1  Med: -16.25 Max: 46.5
Current: 31.5
-43.1
46.5
» EXAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

EXAS Guru Trades in Q2 2014

Chase Coleman 2,000,000 sh (New)
PRIMECAP Management 2,491,300 sh (New)
Louis Moore Bacon 100,000 sh (unchged)
George Soros Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2014

EXAS Guru Trades in Q3 2014

Paul Tudor Jones 18,511 sh (New)
Steven Cohen 468,200 sh (New)
PRIMECAP Management 2,496,300 sh (+0.20%)
Chase Coleman Sold Out
» More
Q4 2014

EXAS Guru Trades in Q4 2014

Steven Cohen 2,482,400 sh (+430.20%)
PRIMECAP Management 2,521,300 sh (+1.00%)
Paul Tudor Jones 9,500 sh (-48.68%)
» More
Q1 2015

EXAS Guru Trades in Q1 2015

PRIMECAP Management 2,526,300 sh (+0.20%)
Paul Tudor Jones Sold Out
Steven Cohen 158,900 sh (-93.60%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - Jun 20, 2014

Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Exact Sciences Corp

Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, and Envision Healthcare Holdings Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, and Envision Healthcare Holdings Inc. Read more...

Ratios

vs
industry
vs
history
P/B 8.11
EXAS's P/B is ranked lower than
83% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. EXAS: 8.11 )
Ranked among companies with meaningful P/B only.
EXAS' s 10-Year P/B Range
Min: 1.5  Med: 6.45 Max: 37
Current: 8.11
1.5
37
P/S 145.79
EXAS's P/S is ranked lower than
97% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.22 vs. EXAS: 145.79 )
Ranked among companies with meaningful P/S only.
EXAS' s 10-Year P/S Range
Min: 8.84  Med: 47.80 Max: 2482
Current: 145.79
8.84
2482
EV-to-EBIT -15.41
EXAS's EV-to-EBIT is ranked lower than
263% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.37 vs. EXAS: -15.41 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAS' s 10-Year EV-to-EBIT Range
Min: -32.7  Med: -10.05 Max: -0.2
Current: -15.41
-32.7
-0.2
Current Ratio 17.69
EXAS's Current Ratio is ranked higher than
97% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. EXAS: 17.69 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s 10-Year Current Ratio Range
Min: 1.02  Med: 8.47 Max: 50.84
Current: 17.69
1.02
50.84
Quick Ratio 17.31
EXAS's Quick Ratio is ranked higher than
97% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. EXAS: 17.31 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s 10-Year Quick Ratio Range
Min: 1.02  Med: 8.47 Max: 50.84
Current: 17.31
1.02
50.84
Days Inventory 103.97
EXAS's Days Inventory is ranked lower than
63% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. EXAS: 103.97 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s 10-Year Days Inventory Range
Min: 169.5  Med: 169.50 Max: 169.5
Current: 103.97
Days Sales Outstanding 100.01
EXAS's Days Sales Outstanding is ranked lower than
77% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.88 vs. EXAS: 100.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s 10-Year Days Sales Outstanding Range
Min: 279.33  Med: 279.33 Max: 279.33
Current: 100.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.27
EXAS's Price/Net Cash is ranked lower than
52% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.85 vs. EXAS: 9.27 )
Ranked among companies with meaningful Price/Net Cash only.
EXAS' s 10-Year Price/Net Cash Range
Min: 2.02  Med: 6.67 Max: 90
Current: 9.27
2.02
90
Price/Net Current Asset Value 8.85
EXAS's Price/Net Current Asset Value is ranked lower than
61% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.23 vs. EXAS: 8.85 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EXAS' s 10-Year Price/Net Current Asset Value Range
Min: 1.98  Med: 6.57 Max: 60
Current: 8.85
1.98
60
Price/Tangible Book 8.09
EXAS's Price/Tangible Book is ranked lower than
71% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.15 vs. EXAS: 8.09 )
Ranked among companies with meaningful Price/Tangible Book only.
EXAS' s 10-Year Price/Tangible Book Range
Min: 1.88  Med: 6.22 Max: 34.23
Current: 8.09
1.88
34.23
Price/Median PS Value 7.00
EXAS's Price/Median PS Value is ranked lower than
98% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. EXAS: 7.00 )
Ranked among companies with meaningful Price/Median PS Value only.
EXAS' s 10-Year Price/Median PS Value Range
Min: 0.22  Med: 1.41 Max: 40.38
Current: 7
0.22
40.38
Earnings Yield (Greenblatt) (%) -6.50
EXAS's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. EXAS: -6.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXAS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -7.5  Med: 0.00 Max: 41.6
Current: -6.5
-7.5
41.6

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 45 153 303
EPS($) -1.73 -1.46 -0.80
EPS without NRI($) -1.73 -1.46 -0.80

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EXK.Germany,
Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonoscopy. As of December 31, 2013, Company owned 10 issued patents and 28 pending patent applications in the United States, and 62 issued patents and 26 pending patent applications in foreign jurisdictions. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
My Stocks Mar 16 2015 
Why I'm Short Exact Sciences - Whitney Tilson Presentation Feb 24 2015 
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, a Oct 27 2014 
CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business Tal Oct 15 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 

More From Other Websites
10-Q for EXACT Sciences Corp. Aug 03 2015
EXACT SCIENCES CORP Files SEC form 10-Q, Quarterly Report Jul 31 2015
Exact Sciences to Participate in August Conferences Jul 30 2015
Exact Sciences to Participate in August Conferences Jul 30 2015
EXACT SCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jul 24 2015
Exact Sciences Could 'Take Off' if Key Product Rates Highly, Says Manager Jul 23 2015
Canadian, Trina Solar Will Bounce Back Says Green Alpha Manager Jul 23 2015
EXACT SCIENCES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 23 2015
EXACT Sciences upgraded by Lake Street Jul 23 2015
Lightning Round: Perfect domestic stock to own Jul 22 2015
Mizuho Reiterates Buy On Exact Sciences, Expects Positive Outcomes On 2 Coming Decisions Jul 21 2015
Exact Sciences (EXAS) Stock Falls on Public Offering Pricing Jul 21 2015
Exact Sciences Announces Pricing of Public Offering of Common Stock Jul 21 2015
Exact Sciences Announces Pricing of Public Offering of Common Stock Jul 21 2015
Edited Transcript of EXAS earnings conference call or presentation 20-Jul-15 2:00pm GMT Jul 20 2015
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares Jul 20 2015
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares Jul 20 2015
Q2 2015 Exact Sciences Corp Earnings Release - Before Market Open Jul 20 2015
Exact Sciences Highlights Cologuard's® Positive Launch Trajectory in Second Quarter 2015 Jul 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK